4D Molecular Therapeutics Hits New 52-Week High of $13.32

4D Molecular Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.32 on June 29, 2026. This achievement marks a notable recovery from its 52-week low of USD 3.68, reflecting a substantial increase in its stock price over the past year. Despite this recent uptick, the company's one-year performance stands at -42.93%, contrasting sharply with the S&P 500's performance of 20.53% during the same period. The market capitalization of 4D Molecular Therapeutics is currently USD 476 million, indicating its position as a microcap entity within the industry. Financial metrics reveal that the company is currently loss-making, with a negative return on equity of -27.72% and a debt-to-equity ratio of -0.79. Additionally, the company does not offer a dividend yield, and its price-to-book ratio stands at 0.94. This recent high underscores the stock's volatility and the dynamic nature of the biotechnology sector.